Research programme: chimeric antigen receptor T cell therapies - ArsenalBio
Latest Information Update: 11 Oct 2022
At a glance
- Originator ArsenalBio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 27 Sep 2022 Arsenal Biosciences and Genentech enterers into a collaboration for the deployment of ArsenalBio’s proprietary technology for high-throughput screening and engineering of T cells, to identify critical success circuits in T cell-based therapies
- 19 Oct 2021 TeneoBio has been acquired and merged into Amgen
- 21 Oct 2020 ArsenalBio in-licenses a single-domain, human heavy chain only antibodies UniDabs® technology from Teneobio